The present invention concerns a compound having the following formula (I): wherein: —A is in particular —N(R′.sub.a)—C(═O)—R, R′.sub.a being H or a (C.sub.1-C.sub.6)alkyl group, and R being preferably a group having the following formula (II): —X is in particular chosen from the group consisting of: —SO.sub.2—N(R′.sub.b)—, R′.sub.b being H or a (C.sub.1-C.sub.6)alkyl group, —N(R″.sub.b)—SO.sub.2—, R″b being H or a (C.sub.1-C.sub.6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma. ##STR00001##

The present invention concerns a compound having the following formula (I): wherein: —A is in particular —N(R′.sub.a)—C(═O)—R, R′.sub.a being H or a (C.sub.1-C.sub.6)alkyl group, and R being preferably a group having the following formula (II): —X is in particular chosen from the group consisting of: —SO.sub.2—N(R′.sub.b)—, R′.sub.b being H or a (C.sub.1-C.sub.6)alkyl group, —N(R″.sub.b)—SO.sub.2—, R″b being H or a (C.sub.1-C.sub.6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma. ##STR00001##

Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer and pancreatic cancer.

The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

A new approach to treatment of hematological malignancies. A GAB1 inhibitor for use in a method of treatment of a hematological malignancy is disclosed. The GAB1 inhibitor may be administered alone, or simultaneously or sequentially with a BTK inhibitor to achieve a synergistic effect.

A new approach to treatment of hematological malignancies. A GAB1 inhibitor for use in a method of treatment of a hematological malignancy is disclosed. The GAB1 inhibitor may be administered alone, or simultaneously or sequentially with a BTK inhibitor to achieve a synergistic effect.

Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one LINE 1 (L-1) endonuclease inhibitor.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.